Frequency distributions of the number of cocoons in <i>Isodontia harmandi</i> nests collected for five years during 2010 to 2015. by Yui Imasaki (12562704)

Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML) by Young Kwang Chae (91317)

“…Furthermore, our findings may provide the basis for a novel CML therapy targeting AQP5.</p></div>…”

Frequency distributions of clutch size in <i>Isodontia harmandi</i> nests collected for five years during 2010 to 2015. by Yui Imasaki (12562704)

Changes in mean evoked rate over time. by Sönke Ahlf (304600)

“…<b>E</b> BF responses of all recorded units; in T animals a significant increase of response strength can be found only at the day of the trauma, immediately post trauma. <b>F</b> Mean evoked rates at least one octave above BF; in T animals an increase of response can be found only from day 2–3 on, while in NT animals the responses decrease already at the day of the trauma. …”

Image_5_2-Methoxyestradiol Protects Against Lung Ischemia/Reperfusion Injury by Upregulating Annexin A1 Protein Expression.TIF by Wen-I Liao (586146)

Transplantation of fecal microbiota from colitis mice disrupted hepatic lipid metabolism in recipient GF mice. by Chungho Lee (8431335)

A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice by Chunbing Zheng (775311)

“…As a result, WB403 exhibited a moderate TGR5 activation effect while promoting GLP-1 secretion efficiently. …”

Mutant p53 proteins have impaired DNA binding and transcriptional regulation. by Nathaniel C. Holcomb (22793595)

Comparison of the amount of locomotor activity (mean counts per day) and the night-day ratio in control and diabetic animals submitted to two light schedules. by Hasna Lahouaoui (595100)

“…STZ-diabetic mice show a significant reduced locomotor activity at 100 (controls: 1681.9±91.6 counts and STZ-diabetic: 1097.5±119.5 counts; p≤0.001) and 300 lux (controls: 2006±108.2 counts and STZ-diabetic: 1620.6±140.7 counts; p≤0.001), whereas at 1000 lux, no significant difference is shown between the two groups (controls: 1833.2±89.9 counts and STZ-diabetic: 1842±108.5 counts). …”

Table5_Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.XLSX by Jian-jian Yin (18067777)

The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies - Fig 2 by Alexandra Meier (5746292)

Number and proportion of study participants who fulfilled the WHO recommendations PA for people aged over 65 years, separately for intervention and control group (N = 166). by Fabian Kleinke (4787655)

Subjects:

Descriptive characteristics of the study sample (N = 166), complete and valid data sets (baseline, 3 and 6 months follow-up). by Fabian Kleinke (4787655)

Subjects:

Consort diagram: Recruited participants and participants included in the analysis (N = 166). by Fabian Kleinke (4787655)

Subjects:

Dataset. by Fabian Kleinke (4787655)

Subjects:

Image1_v1_Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier.TIF by Jiyuan Tu (572853)

Image1_v1_Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier.TIF by Jiyuan Tu (572853)

Table1_v1_Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier.DOCX by Jiyuan Tu (572853)

Table1_v1_Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier.DOCX by Jiyuan Tu (572853)

Fig 9 - by Sue E. Moore (2932644)